loteprednol etabonate 0.25% ophthalmic suspension
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Corneal Endothelial Dystrophy
Conditions
Corneal Endothelial Dystrophy, Corneal Edema
Trial Timeline
Nov 23, 2021 → Sep 5, 2023
NCT ID
NCT05136443About loteprednol etabonate 0.25% ophthalmic suspension
loteprednol etabonate 0.25% ophthalmic suspension is a approved stage product being developed by Kala Pharmaceuticals for Corneal Endothelial Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT05136443. Target conditions include Corneal Endothelial Dystrophy, Corneal Edema.
What happened to similar drugs?
2 of 3 similar drugs in Corneal Endothelial Dystrophy were approved
Approved (2) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05136443 | Approved | Completed |
Competing Products
12 competing products in Corneal Endothelial Dystrophy